---
title: "AbbVie piles on $8 billion in debt for its Apogee deal -- should dividend investors worry?"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295533701.md"
description: "The pharmaceutical company hopes that another big-time acquisition will pay off."
datetime: "2026-08-11T12:04:41.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295533701.md)
  - [en](https://longbridge.com/en/news/295533701.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295533701.md)
generator: "portal-rs"
---

# AbbVie piles on $8 billion in debt for its Apogee deal -- should dividend investors worry?

The pharmaceutical company hopes that another big-time acquisition will pay off.

### Related Stocks

- [APGE.US](https://longbridge.com/en/quote/APGE.US.md)
- [ABBV.US](https://longbridge.com/en/quote/ABBV.US.md)

## Related News & Research

- [Trivium Point Advisory LLC Increases Stock Holdings in AbbVie Inc. $ABBV](https://longbridge.com/en/news/297292955.md)
- [AbbVie Inc Stock (ABBV) Moved Up by 3.35% on Jul 28: A Full Analysis](https://longbridge.com/en/news/294086753.md)
- [ANI Pharma CEO Nikhil Lalwani disposes of 5,400 common shares worth $401,220](https://longbridge.com/en/news/297093829.md)
- [Ligand targets $150-$250 million in annual investments as royalty revenue tops $225 million in 2026 guidance](https://longbridge.com/en/news/297061481.md)
- [MrBeast, Snapchat, AI and more: Pharma marketing’s pulse check](https://longbridge.com/en/news/297343211.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**